

ARANESP (darbepoetin alfa) Infusion Order

intake@sageinfusion.com | www.sageinfusion.com/SubmitOrder

PATIENT INFORMATION				
Patient Name:	DOB:		Gender: □ M □ F	
Address:	City: _		State:	ZIP:
Phone:	Email:		Ht:	Wt:
Please Attach: Insuran	nce cards 🔲 History 8	ι Physical □ M	ost recent labs	☐ Medication list
□ NKDA □ Allergies:				
PRESCRIBER INFORMATION	N			
Ordering Provider Name: _				
Provider NPI:		Phone: Fax: _		ax:
Practice Address:		City:	State:	ZIP:
REQUIRED INFORMATION				
Documentation:				
☐ Recent clinical and/or of	fice visit notes supporting pr	imary diagnosis		
☐ Recent Labwork: CBC, Iro	on Stuides, Ferritin (please at	tach)		
□ New to Therapy □ Co DOSING/FREQUENCY: □ Aranesp, administer su Dose: □ 25 mcg □ 4	□ Other: Dentinuation of Therapy: Den	ate of last dose (if ap ncg □ 200 mcg onths (please specify	lease indicate stage (if plicable): Other:	applicable):
Sage Infusion Standing Ord	ders:			
☑ Provide treatment under Action Plan for Infusion R		delines, Medication Sa	afety Protocol, Emerge	ency Guidelines, and
Provider Name	Provider Signature		Date	
In controlled clinical trials of patient other ESAs increased the risk of dea thromboembolic events in the high	ith, myocardial infarction, stroke, co	oglobin targets (13 - 14 g ongestive heart failure, thr	/dL) to lower targets (9 – 11 ombosis of hemodialysis va	.3 g/dL), epoetin alfa and scular access, and other
Fax Number ☐ Brandon: (656) 218-9643 ☐ Clearwater: (727) 977-9717 ☐ Fort Myers: (239) 533-5962 ☐ Gainesville: (352) 450-8886 ☐ Lakeland: (863) 777-2528	☐ Ocala: (352) 565-: ☐ Orlando: (407) 79 ☐ Sarasota: (941) 41 ☐ St. Petersburg: (73 ☐ Tampa: (813) 775-	2-6558 3-3280 27) 977-8836	☐ The Villages Lake	nwood: (352) 450-3080 Sumter: (352) 565-5553 sh Springs: (352) 810-3536 0779